Extracellular vesicles (EVs) have gained attention in the cosmetics industry for their role in intercellular communication and tissue regeneration. They transfer bioactive molecules such as proteins, lipids, and nucleic acids, promoting skin repair, rejuvenation, and anti-aging effects. Human mesenchymal stem cell-derived EVs are particularly valued for their ability to enhance collagen production, reduce inflammation, and improve skin texture and hydration. However, their use is prohibited by regulatory agencies. Plant- and bacterial-derived EVs are being explored to meet the demand for innovative cosmetics. Despite their potential, challenges such as regulatory approval, high production costs, and product stability need to be addressed to fully realize the benefits of EV-based cosmetics. This paper examines the mechanisms, benefits, market trends, and prospects of EV-based skincare products, highlighting their transformative impact on the cosmetic industry.

Facial aging is primarily characterized by the loss and disorganization of the dermal extracellular matrix (ECM), particularly collagen. Injectable biostimulators, such as calcium hydroxyapatite (CaHA), represent a vital non-surgical strategy to counteract these changes by inducing neocollagenesis. This 90-day clinical trial was designed to comparatively evaluate the efficacy of a novel regenerative solution (RS) diluent, formulated to potentially enhance the biostimulatory effects of standard CaHA (STIIM product), against a conventional diluent (control) for the treatment of facial laxity. Twenty-one subjects (N = 21) were randomized to receive CaHA diluted with either RS or control formulation. Efficacy was assessed using histological analysis (collagen I area percentage), ultrasound (US) for dermal density, and clinical laxity scoring. Histological analysis, although limited by a small subsample size (N = 3), showed qualitative and exploratory evidence of collagen remodeling in both groups. However, the RS group showed enhanced dermal thickening via US (15% increase vs. 5% control, p-value = 0.012), and improvement in clinical laxity. Furthermore, histological findings, including Picrosirius red staining, indicated that the RS group resulted in qualitatively greater ECM organization and more robust type I collagen fibers compared to the control. The novel regenerative solution is safe and demonstrates enhanced neocollagenesis and clinical efficacy over the conventional formulation, validating its potential as a diluent for CaHA for optimized facial rejuvenation.